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To the editor: 
The interesting letter to the editor by Mecabo et al.1 sheds new perspective on the 
correlation of lactate dehydrogenase (LDH) and hemolysis in patients with sickle 
cell anemia (SCA). Their data show that LDH-3 seems to be the isoenzyme that is 
correlated with hemolysis. Accordingly, LDH-3 could be a useful marker in future 
studies to determine the source of elevated levels of serum LDH in patients with 
SCA as well as in other diseases. Expense, insurance approval and clinical 
availability, however, may hamper its availability on a routine basis. Moreover and 
unlike previous reports,2,3 Mecabo et al.1 found that hydroxyurea (HU) did not 
show reduction of  LDH or other hemolytic parameters in patients with SCA taking 
HU. Lactate dehydrogenase-3, however, was decreased in patients with SCA 
taking HU. 
Given the above new information, I wish to clarify two issues pertinent to this 
controversial subject. Since sickle cell disease (SCD) is a hemolytic disorder, all its 
variants have variable degrees of hemolysis and, hence, have variable degrees of 
elevated LDH levels that are most severe in SS.  In a subset of patients with SCA 
and uncomplicated vaso-occlusive crises (VOC) a hyperhemolytic state was 
characterized by 40% decrease in the mean red blood cell (RBC) t1/2 survival 
determined by 51Cr   method, 53% decrease in total cell life, 54% increase in the 
destructive rate of RBC with a significant 58% increase in LDH and changes in 
other parameters of hemolysis compared to steady state values.4 The mean or 
median levels in patients with hemolysis or hyperhemolysis are usually < 1000 
U/L.1,4 Levels of LDH > 1000 U/L suggest additional sources of the enzyme with 
or without hemolysis or hyperhemolysis especially if other parameters of 
hemolysis are absent.  Such high levels of LDH could be a sign of co-existent 
tissue damage due to SCA. Elevated levels of LDH are also known to be markers 
of testicular germ cell tumors and of melanoma. 5 In stage 3 testicular cancer the 
LDH value could be more than 10 times the upper limit of the reference range. 6 
Moreover, in multiple myeloma (MM) a high level of LDH is a poor prognostic 
sign despite the fact that hemolysis is not an issue in MM.7 Similarly, it would be 
instructive to use the LDH values or, even better, the LDH-3 values to rate the 
severity of hemolysis and the presence or absence of organ damage in SCD. 
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The second issue pertains to the effect of HU on the hemolytic parameters in 
patients with SCA.  We have prospectively studied the erythropoietic activity in 
patients with SCA before and after treatment with HU.8 Some of the patients were 
enrolled in the double-blind placebo controlled trial of HU in patients with SCA 
(also known as the MSH study) and others were enrolled in an open label study. 
Determinants of erythropoietic activity included, among other things, hemoglobin 
(Hb), mean corpuscular volume (MCV), reticulocyte count, Hb F, RBC survival by 
the 51Cr method, RBC life span and RBC production/destruction rate.  As shown in 
Table 1 responders to HU showed significant increase in MCV, Hb F, RBC 
survival, cell life and in the production/destruction rate and significant decrease in 
the reticulocyte count. Non-responders to HU and the placebo group showed no 
difference before and after HU therapy. Moreover there was positive significant 
correlation between Hb F level and RBC survival. The study by Mecabo et al1 did 
not analyze the hemolytic parameters in terms of clinical response to HU and of 
Hb F level that, apparently, was not determined. Furthermore, the authors stated 
that the hemolytic parameters in the HU group were not statistically different from 
the SS group that did not receive HU. Accordingly, it seems that the majority of 
the patients taking HU were nonresponders and that may explain why the trial have 
failed to show the beneficial effects of HU on RBC survival.  
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